UY32461A - Sal de tosilato de 6-metil-5-(metil-1h-pirazol-5-il)-n-{[e-(metilsulfonil)piridin-2-il]metil -2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida - Google Patents

Sal de tosilato de 6-metil-5-(metil-1h-pirazol-5-il)-n-{[e-(metilsulfonil)piridin-2-il]metil -2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida

Info

Publication number
UY32461A
UY32461A UY0001032461A UY32461A UY32461A UY 32461 A UY32461 A UY 32461A UY 0001032461 A UY0001032461 A UY 0001032461A UY 32461 A UY32461 A UY 32461A UY 32461 A UY32461 A UY 32461A
Authority
UY
Uruguay
Prior art keywords
methyl
oxo
phenyl
dihidropiridin
metilsulfonil
Prior art date
Application number
UY0001032461A
Other languages
English (en)
Inventor
Ms Helena Nicklasson
Lars-Erik Briggner
Per Tomas Klingstedt
Marie-Lyne Alcaraz
Robert Anthony Nixon
Watts Andrew
Hans Roland Loenn
Zuban Robert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32461(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY32461A publication Critical patent/UY32461A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan 4-metilbencenosulfonato de 6-metil-5-(1metil-1H-pirazol-5-il)-N-{[5-(metilsulfonil)piridin-2-il]metil -2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida y una modificación cristalina nueva del mismo, junto con los procesos para preparar dicha sal y modificación, las composiciones farmacéuticas que comprenden dicha modificación, y el uso de dicha modificación en terapia.
UY0001032461A 2009-02-20 2010-02-19 Sal de tosilato de 6-metil-5-(metil-1h-pirazol-5-il)-n-{[e-(metilsulfonil)piridin-2-il]metil -2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida UY32461A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15409909P 2009-02-20 2009-02-20

Publications (1)

Publication Number Publication Date
UY32461A true UY32461A (es) 2010-09-30

Family

ID=42046174

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032461A UY32461A (es) 2009-02-20 2010-02-19 Sal de tosilato de 6-metil-5-(metil-1h-pirazol-5-il)-n-{[e-(metilsulfonil)piridin-2-il]metil -2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida

Country Status (15)

Country Link
US (2) US8232296B2 (es)
EP (1) EP2398792B1 (es)
JP (1) JP5543982B2 (es)
KR (1) KR20110127158A (es)
CN (1) CN102405219B (es)
AR (1) AR075523A1 (es)
AU (1) AU2010215269B2 (es)
BR (1) BRPI1008396B8 (es)
CA (1) CA2752319C (es)
ES (1) ES2469916T3 (es)
MX (1) MX2011008389A (es)
RU (1) RU2526038C2 (es)
TW (1) TW201036957A (es)
UY (1) UY32461A (es)
WO (1) WO2010094964A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
CA2703996A1 (en) * 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2671614A1 (en) * 2007-12-21 2013-12-11 University of Rochester Molecular Targets for Treatment of Inflammation
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
RU2012116877A (ru) * 2009-10-02 2013-11-10 Астразенека Аб Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
EA025504B1 (ru) * 2012-09-26 2016-12-30 Далянь Инститьют Оф Кемикал Физикс, Чайниз Академи Оф Сайэнс Молекулярное сито sapo-34 и способ его получения
DK2902362T3 (en) * 2012-09-26 2017-08-07 Dalian Inst Chemical Physics Cas SAPO-34 MOLECULE AND SYNTHESIS PROCEDURES
MX370175B (es) * 2013-03-06 2019-12-04 Novartis Ag Formulaciones de compuestos orgánicos.
RU2542100C1 (ru) * 2013-12-24 2015-02-20 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской Академии Наук (ИХС РАН) Сокристаллическая форма теофиллина с дифлунисалом или диклофенаком
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
EP3256422B1 (en) * 2015-02-12 2022-04-06 Basf Se Process for the preparation of a dealuminated zeolitic material having the bea framework structure
US20160257573A1 (en) * 2015-03-03 2016-09-08 Uop Llc High surface area pentasil zeolite and process for making same
JP7041146B2 (ja) * 2016-10-28 2022-03-23 アストラゼネカ・アクチエボラーグ （１Ｒ，２Ｒ）－２－［４－（３－メチル－１Ｈ－ピラゾール－５－イル）ベンゾイル］－Ｎ－（４－オキソ－４，５，６，７－テトラヒドロピラゾロ［１，５－ａ］ピラジン－３－イル）シクロヘキサンカルボキサミド
WO2021053058A1 (en) 2019-09-17 2021-03-25 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
CN112851643B (zh) * 2019-11-28 2024-01-16 广东东阳光药业股份有限公司 嘧啶苯甲酰胺化合物的盐酸盐及其用途
LT4106757T (lt) 2020-04-16 2023-11-10 Mereo Biopharma 4 Limited Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui
CN114075135B (zh) * 2020-08-10 2024-06-11 上海润石医药科技有限公司 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
US20240101569A1 (en) * 2021-01-27 2024-03-28 Intra-Cellular Therapies, Inc. Salt crystals
JP2024540952A (ja) 2021-10-20 2024-11-06 メレオ バイオファーマ ４ リミテッド 線維化の治療における使用のための好中球エラスターゼ阻害剤
EP4438606A4 (en) * 2021-12-23 2025-04-09 Shenzhen Antiv Pharma Co., Ltd. NEW CRYSTALLINE FORM OF A NUCLEOSIDE COMPOUND AND ITS SALT
IL327315A (en) 2023-10-11 2026-05-01 Mereo Biopharma 4 Ltd Elovastat and alpha-1 antitrypsin for the treatment of respiratory disorders
IL327395A (en) 2023-12-21 2026-05-01 Mereo Biopharma 4 Ltd Use of ALVELESTAT in specific patients
GB202319953D0 (en) 2023-12-22 2024-02-07 Mereo Biopharma 4 Ltd Tablet formulations involving alvelestat

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH02152966A (ja) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd ４−ヒドロキシカルボスチリル誘導体
US5521179A (en) 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
JPH1171351A (ja) 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
PT1300396E (pt) 2000-06-12 2009-04-20 Eisai R&D Man Co Ltd Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização
KR100828982B1 (ko) 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
JP4370164B2 (ja) 2001-08-14 2009-11-25 富山化学工業株式会社 新規なウイルス増殖阻害・殺ウイルス方法および新規なピラジンヌクレオチド・ピラジンヌクレオシド類似体
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
SE0104251D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP2130820A1 (en) 2002-02-19 2009-12-09 Shionogi & Co., Ltd. Antipruritics
CA2496815C (en) 2002-08-27 2011-04-26 Bayer Healthcare Ag Dihydropyridinone derivatives
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
US7629362B2 (en) 2003-02-13 2009-12-08 Banyu Pharmaceutical Co., Ltd. 2-pyridine carboxamide derivatives
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
ATE435862T1 (de) 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
ES2367699T3 (es) 2004-02-19 2011-11-07 Bayer Pharma Aktiengesellschaft Derivados de dihidropiridinona.
WO2005082864A1 (en) 2004-02-26 2005-09-09 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1786813A2 (en) 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
MX2008011963A (es) 2006-03-20 2008-10-01 Pfizer Ltd Derivados de amina.
NZ572250A (en) 2006-05-04 2011-10-28 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2044056B1 (en) 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
TW200821316A (en) 2006-07-19 2008-05-16 Astrazeneca Ab Novel compounds 243
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
BRPI0719270A2 (pt) 2006-10-04 2014-03-11 Pfizer Ltd Derivados de sulfonamida como agonistas adrenérgicos e antagonistas muscarínicos
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008075005A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
SA08280783B1 (ar) 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
BRPI0807004A2 (pt) 2007-02-07 2014-04-15 Argenta Discovery Ltd Sal
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
TW200843759A (en) 2007-02-15 2008-11-16 Argenta Discovery Ltd Compounds and their use II
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
RU2479580C2 (ru) 2007-06-27 2013-04-20 Астразенека Аб Производные пиразинона и их применение для лечения легочных заболеваний
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
CA2703996A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
KR101273200B1 (ko) 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB0811099D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
US7862384B2 (en) * 2008-07-07 2011-01-04 Myers Kelly H Repair adapter for a modular plug
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Also Published As

Publication number Publication date
CN102405219A (zh) 2012-04-04
RU2011135627A (ru) 2013-03-27
EP2398792A1 (en) 2011-12-28
KR20110127158A (ko) 2011-11-24
JP2012518623A (ja) 2012-08-16
RU2526038C2 (ru) 2014-08-20
CA2752319C (en) 2016-10-04
MX2011008389A (es) 2011-09-01
JP5543982B2 (ja) 2014-07-09
US20120269872A1 (en) 2012-10-25
CA2752319A1 (en) 2010-08-26
BRPI1008396B1 (pt) 2020-11-10
EP2398792B1 (en) 2014-04-09
BRPI1008396B8 (pt) 2021-05-25
TW201036957A (en) 2010-10-16
WO2010094964A1 (en) 2010-08-26
ES2469916T3 (es) 2014-06-20
AU2010215269A1 (en) 2011-08-25
AU2010215269B2 (en) 2013-06-27
AR075523A1 (es) 2011-04-06
US8232296B2 (en) 2012-07-31
US20100216843A1 (en) 2010-08-26
CN102405219B (zh) 2013-11-06
BRPI1008396A2 (pt) 2017-06-27
HK1162498A1 (en) 2012-08-31

Similar Documents

Publication Publication Date Title
MX2011008389A (es) Sal de tipo tosilato de un derivado de 5-pirazolil-2-piridona, util en el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
EA201000774A1 (ru) Ингибиторы бета-лактамазы
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0822121A2 (pt) Composição para cuidado oral, e uso da mesma
BRPI1014034A2 (pt) formulação e seu uso, composição, solução injetável e kit.
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
PE20141406A1 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
MX2015017036A (es) Metodo para producir celulas progenitoras renales y farmaco que comprende las mismas.
DOP2014000133A (es) Triazolopiridinas sustituidas
NI201000079A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrófilos.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2014000131A1 (es) Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada que comprende pirfenidona; y su uso para el tratamiento o regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica.
DOP2013000244A (es) Triazolopiridinas
UY33452A (es) Triazolopiridinas sustituidas
BR112013002553A2 (pt) implantes à base de colágeno para distribuição sustentada de drogas
MX2009010103A (es) Composiciones estructuradas que comprenden una arcilla.
AR053803A1 (es) Uso de acido pinolenico
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
SG182629A1 (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20130124